NCT05982873

Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to telisotuzumab adizutecan prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 1, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 9, 2023

Completed
Last Updated

February 6, 2026

Status Verified

September 1, 2025

First QC Date

August 1, 2023

Last Update Submit

February 4, 2026

Conditions

Solid Tumors

Keywords

Expanded AccessPre-approval AccessCompassionate UseSpecial Access ProgramNamed Patient BasisSpecial Access Scheme

Interventions

Telisotuzumab AdizutecanDRUG

Intravenous (IV) Infusion

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • There are other suitable treatment options.
  • The participant qualifies for ongoing clinical trials.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Links

Study Officials

  • ABBVIE INC.

    AbbVie

    STUDY DIRECTOR

Central Study Contacts

ABBVIE CALL CENTER

CONTACT

844-663-3742abbvieclinicaltrials@abbvie.com

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 1, 2023

First Posted

August 9, 2023

Last Updated

February 6, 2026

Record last verified: 2025-09